Bestselling Author’s Online Auction Aims to Raise $500,000 for Diabetes Research to Support a Near-Term Cure

Share Article

Proceeds from Brenda Novak’s 10th annual fundraising event will be directed exclusively to a near-term cure with help from the Juvenile Diabetes Cure Alliance.

New York Times best-selling author Brenda Novak announced today that all of the proceeds from her tenth annual diabetes research fundraiser will be directed toward a near-term cure for type 1 diabetes. As in previous years, Novak will work with the Juvenile Diabetes Cure Alliance (JDCA) to legally stipulate that auction funds only support practical cure research.

In the past decade, the Brenda Novak for the Cure of Diabetes auction has raised a total of $2 million for type 1 diabetes research. In 2013, Novak first worked with the JDCA to ensure that funds from the auction were dedicated to projects most likely to produce a cure for the current rather than future generations of diabetics. Novak began the auction in honor of her son Thad, who was diagnosed with type 1 as a child, and says that stipulation helps ensure that her son is most likely to see a cure in his lifetime.

“When Thad was diagnosed with type 1, doctors told us a cure would be found before he went to high school. He’s now 17 and we know a cure isn’t possible without continued funding,” said Novak. “After collaborating with the JDCA, I’m convinced a near-term, practical cure is possible. I’m excited to be working with them to legally ensure that funds from the auction go toward research projects most likely to help Thad and others.”

Founded in 2011, the JDCA serves as a donor advocate and advisor within the type 1 diabetes space. By issuing reports on cure progress and advising donors on how to support a near-term cure, the independent, nonprofit organization seeks to realize a practical cure before 2025. A practical cure would eliminate carbohydrate counting, daily blood sugar testing, the worry of going low overnight and other burdens of diabetic life.

“We’re thrilled that Brenda has decided to work with us to stipulate for another year,” said Phil Shaw, JDCA general manager and a 20-year management veteran. “We’re striving to advance research for a near-term cure, but need assistance from donors. Stipulation is legally binding and the most powerful tool a donor has to encourage nonprofit accountability and further progress.”

To participate in the auction, visit For more information on the JDCA and its donor services, visit

About Brenda Novak
It was a shocking experience that jump-started Brenda Novak 's author career. "I caught my day-care provider drugging my children with cough syrup to get them to sleep while I was away," Brenda says. "It was then I decided that I needed to do something from home." Now she is a New York Times and USA Today Bestseller, and many of her books have been designated an RT Book Review Magazine "Top Pick" and have gone on to place in contests such as the Romance Writers of America Rita Award, the National Readers' Choice, the Bookseller's Best, the Write Touch Readers' Award, and the Book Buyer's Best. Brenda has given writing workshops at various RWA events, RT Book Review Magazine conventions, California Fiction Writer meetings, women's groups and library events. For more about Brenda, visit, where you can find excerpts of her work, prize drawings, book trailers, freebies and information about her annual on-line auction for diabetes research which she holds every May in honor of her son and the many others who face this terrible disease.

About the JDCA
The JDCA is an independent analyst of the type 1 diabetes charitable universe and brings a business-like perspective to help donors focus research toward a practical cure. The mission of the JDCA is to achieve a type 1 practical cure before 2025 by steering donor contributions to the most effective charities.

Become an Alliance member:
Become a fan on Facebook:
Follow us on Twitter:

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kikora Mason
Walker Sands Communications
+1 (312) 648-6009
Email >
Visit website